Use my Search Websuite to scan PubMed, PMCentral, Journal Hosts and Journal Archives, FullText. Kick-your-searchterm to multiple Engines kick-your-query now !>

A dictionary by aggregated review articles of nephrology, medicine and the life sciences Your one-stop-run pathway from word to the immediate pdf of peer-reviewed on-topic knowledge.

10.1007/s00115-020-00937-6 http://scihub22266oqcxt.onion/10.1007/s00115-020-00937-6 32524163!7286209!32524163     free     free     free       Nervenarzt 2020 ; 91 (8): 722-734 Nephropedia Template TP {{tp|p=32524163|t=2020. Ocrelizumab zur Behandlung der Multiplen Sklerose |pdf=|usr=}}{{32524163}} gab.com Text Ocrelizumab zur Behandlung der Multiplen Sklerose JO: Nervenarzt http://www.kidney.de/pget.php?&tw=1&pmid=32524163 #FOAvip Ocrelizumab is a monoclonal antibody directed against the differentiation antigen CD20, which leads to an effective long-term depletion of lymphocytes, in particular B cells. Recently published phase 3 studies confirmed that ocrelizumab is effective in the treatment of both relapsing multiple sclerosis (RMS) and primary progressive multiple sclerosis (PPMS). Based on these results, ocrelizumab was the first drug to be approved for primary chronic progressive MS. To place this therapeutic breakthrough in the context of the current MS therapeutic landscape, it is worthwhile taking a look back at the development of antibody-mediated CD20 depletion, the studies underlying the approval of ocrelizumab and their open extension phases. This review article discusses the available data on the efficacy and safety of long-term B?cell depletion in MS patients and reviews current knowledge on the role of B?lymphocytes in the immunopathogenesis of MS. Twit Text FOAVip Ocrelizumab zur Behandlung der Multiplen Sklerose ????Nervenarzt http://www.kidney.de/pget.php?&tw=1&pmid=32524163 #FOAvip Twit Text # Free Paper on # # # # # LINK http://www.kidney.de/pget.php?&tw=1&pmid=32524163 #FOAvip English Wikipedia <ref>{{Cite pmid|32524163}}</ref> Ocrelizumab zur Behandlung der Multiplen Sklerose #MMPMID32524163 Graf J; Albrecht P; Goebels N; Aktas O; Hartung HP Nervenarzt 2020[Aug]; 91 (8): 722-734 PMID32524163show ga Ocrelizumab is a monoclonal antibody directed against the differentiation antigen CD20, which leads to an effective long-term depletion of lymphocytes, in particular B cells. Recently published phase 3 studies confirmed that ocrelizumab is effective in the treatment of both relapsing multiple sclerosis (RMS) and primary progressive multiple sclerosis (PPMS). Based on these results, ocrelizumab was the first drug to be approved for primary chronic progressive MS. To place this therapeutic breakthrough in the context of the current MS therapeutic landscape, it is worthwhile taking a look back at the development of antibody-mediated CD20 depletion, the studies underlying the approval of ocrelizumab and their open extension phases. This review article discusses the available data on the efficacy and safety of long-term B?cell depletion in MS patients and reviews current knowledge on the role of B?lymphocytes in the immunopathogenesis of MS. |*Multiple Sclerosis/drug therapy[MESH] |Antibodies, Monoclonal, Humanized/*therapeutic use[MESH] |Humans[MESH]Ocrelizumab zur Behandlung der Multiplen Sklerose (epmc).pdf DeepDyve Pubget Overpricing